Passage Bio

Did you know progranulin is vital for brain cell health, and increasing its levels could benefit patients with both FTD-C9orf72 and FTD-GRN? Thanks to positive FDA feedback, we are expanding our upliFT-D trial to include individuals with C9orf72 gene mutations, marking a major milestone in treatment access. Learn more about this exciting news here: https://loom.ly/qMRn2rw

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (GLOBE NEWSWIRE) - P...

ICYMI: TV recently joined us at our Philadelphia HQ to discuss our groundbreaking work in treating . Watch the full video to learn about what's on the horizon for Passage Bio here: https://loom.ly/4KgAgjc

Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients treated, and previews an upcoming conference in September.Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy

Passage Bio will be participating in the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13 and the 15th Annual Wedbush PacGrow Healthcare Conference in New York City on August 14. Our leadership team is eager to present our latest corporate updates and upcoming milestones. Discover more about our presence and what to expect here: https://loom.ly/NQfz__U

We are pleased to announce the out-licensing of our pediatric lysosomal storage disease programs to Gemma Biotherapeutics, a new company founded by James M. Wilson, M.D., Ph.D., that is committed to advancing promising gene therapies for children with , , and . This strategic move extends our cash runway, enabling us to continue our vital work in adult neurodegenerative diseases.

Additionally, Passage Bio will launch a new research partnership with Gemma Biotherapeutics that will leverage our combined expertise to explore new frontiers in CNS research. Read more here: https://loom.ly/EC6p40I

Did you know that Progranulin (PGRN) could unlock breakthroughs in the treatment of neurodegenerative diseases? At Passage Bio, we are exploring the therapeutic potential of elevating PGRN levels in the central nervous system to alter the course of neurodegenerative diseases. Discover more here: https://loom.ly/GtdTEMQ

Passage Bio, Inc. - Our Science - Role of Progranulin

If you or a loved one has , genetic counseling and testing are essential. It can pinpoint if a mutation caused your FTD, provide insights into your symptoms, and identify clinical trial eligibility, such as the upliFT-D trial for FTD-GRN. InformedDNA offers free genetic testing and counseling for US residents. Learn more here: https://loom.ly/hm5g0lc

Passage BIO FTD No-Cost Genetic Counseling and Testing Available for Frontotemporal Dementia InformedDNA is providing no-cost genetic testing and counseling to patients with Frontotemporal Dementia (also known as frontotemporal degeneration or FTD). FTD is the most common form of dementia in people younger than 60....

We are thrilled to share that Passage Bio has received positive feedback from the FDA on expanding our upliFT-D trial of PBFT02 to include patients with frontotemporal dementia ( ) due to C9orf72 gene mutations. This expansion is a significant milestone in our mission to improve the lives of patients with neurodegenerative diseases. Read more here: https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2024/Passage-Bio-Announces-Positive-Feedback-from-FDA-on-Expansion-of-upliFT-D-Trial-of-PBFT02-to-Include-FTD-C9orf72-Patients/default.aspx

Check out our recent podcast appearance! Our CEO Will Chou, MD, recently joined the Life Science Success Podcast to share updates from our ongoing clinical study for , the urgency of developing treatments for genetic mutations, and the potential impact on patients and their families. Tune in for insights here: https://loom.ly/XCh2t9E

Dr. William Chou on Gene Therapy for Neurodegenerative Diseases In this episode of the Life Science Success Podcast, host Don Davis, PhD, MBA, interviews Dr. William Chou of Passage Bio. Dr. Chou discusses his transition from a …

As Alzheimer's & Brain Awareness Month comes to a close, we reflect on our ongoing commitment to advance gene therapies that have the potential to change the lives of patients and their families with neurodegenerative conditions. We are proud to continue our work advancing research and developing treatments that address the urgent needs of the neurodegenerative disease community. Learn more about our ongoing efforts here: https://loom.ly/WkGeVEQ

Passage Bio, Inc. - Our Science - Our Approach Passage Bio is exploring genetic medicines that work by delivering functional therapeutic genes to patients with diseases where genes are mutated, nonfunctional, or missing. Genetic drug development is especially difficult for neurodegenerative disorders due to challenges in crossing the blood-brain...

Last week, our Passage Bio team had an unforgettable summer team-building event at Grounds for Sculpture. This museum, sculpture garden, and arboretum offered the perfect blend of art and nature, with nearly 300 contemporary sculptures across 42 landscaped acres and six galleries showcasing amazing exhibitions.

With colleagues spread across different locations, we truly value the time we can spend together!

Passage Bio recognizes , the oldest nationally celebrated commemoration of the ending of slavery in the United States. We are proud to give our employees the day off to reflect, educate themselves, and engage in meaningful conversations about race and justice.

Explore a curated Juneteenth reading list with resources that highlight the significance of this day here: https://loom.ly/2IuxQcA

nmaahc.si.edu

We are proud to sponsor the Philadelphia Million Dollar Bike Ride, an annual event in our hometown that has channeled over $17 million into rare disease research. Learn more about this special event, coming up this Saturday, here: https://loom.ly/6I1gXvI

Join us next week at the Goldman Sachs Global Healthcare Conference on June 12th at 4:00 PM ET to hear the latest corporate updates from our CEO, Dr. Will Chou. Secure your spot and register for the webcast today! https://loom.ly/pISWesY

June is Alzheimer’s & Brain Awareness Month, which hits close to home for Passage Bio and all of the families affected by these devastating conditions.

Worldwide, there are an estimated 47 million people living with Alzheimer’s and other dementias. Without a change, these numbers are expected to grow to 76 million by 2030. Learn more about how you can take action: www.alz.org/abam.

Today, as we honor Memorial Day, Passage Bio pays tribute to the brave men and women who have made the ultimate sacrifice in service to our country. 🇺🇸 Their unwavering commitment to protecting our nation inspires us every day.

We’re excited to announce Carrie Gordon, a Drexel University sophomore, as the third recipient of the Tachi Yamada Scholarship! Carrie’s dedication to neurology and passion for volunteerism make her a worthy recipient of this award. Read the full press release here: https://loom.ly/R7UC-38

Progranulin is a protein made by the GRN gene which plays a critical role in safeguarding the health and survival of different types of cells. Learn more about the importance of progranulin levels in relation to : https://loom.ly/GtdTEMQ

: Today, there are approximately 41,000 symptomatic Americans living with and more than 200,000 at risk of inheriting it, according to Huntington's Disease Society of America .

Passage Bio is proud to stand with the HD community this as we work towards improving the lives of people with neurodegenerative diseases.

The Passage Bio team attended The Association for Frontotemporal Degeneration 2024 Education Conference this past week! We were inspired to hear from patients and their family members as they shared their journeys.

This , we helping to raise awareness of the disease and showing our support for the caregivers, families, and patients who are affected. Passage Bio joins the fight against by continuing to work towards improving the lives of people with : https://loom.ly/WkGeVEQ

Happy from all of us at Passage Bio! 🧬 Today we are celebrating all the advancements made in the space that have helped pave the way for our vision of delivering life-transforming medicines that can permanently redefine the course of devastating diseases. Learn more about our work in genetic medicine: https://loom.ly/hkMUF98

Members of our Passage Bio team will be making an appearance virtually at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29! President and CEO, Will Chou, MD, and Senior Vice President of Technical Operations, Eden Fucci will participate in a at 9 am ET to discuss the latest considerations and for and manufacturing. For more information, visit: https://loom.ly/NQfz__U

Passage Bio is studying a potential new therapy called PBFT02 for the treatment of frontotemporal dementia caused by a GRN mutation. FTD is a form of early onset dementia with no approved disease-modifying therapies. To learn more about our active and work to develop an effective treatment for FTD, visit: www.ftdclinicaltrial.com

Our team had the pleasure of attending and proudly sponsoring The Association for Frontotemporal Degeneration Hope Rising Benefit last week in New York City. The evening was filled with engaging discussions and connecting with fellow . We are immensely grateful for the opportunity to support such a worthy cause and stand alongside passionate individuals dedicated to supporting those affected by and drive to a cure.

In recognition of , Passage Bio is highlighting the importance of prioritizing health equity and building healthier communities. As we continue to develop genetic medicines that can alter the course of diseases, we are inspired by our peers and the progress they are making. To learn more, visit: https://loom.ly/FpLi6Aw

We are thrilled to share that Passage Bio's Tachi Yamada Scholarship has been featured in Philadelphia Patch's latest article, highlighting our commitment to nurturing the next generation of innovators. Learn more about our program which will support a rising a junior student enrolled in a life science program at a Pennsylvania-based four-year college: https://loom.ly/P3CgmNY

patch.com

National Public Health Week gives us a chance to come together with organizations, healthcare professionals, and individuals around the globe to highlight the vital importance of prioritizing . At Passage Bio, we contribute by advancing gene therapies to improve the lives of patients with . Learn how you can make a difference here: https://loom.ly/h6h9K6E